The changing face of oncology development – is cancer still ‘different’? A US perspective


Oncology development has traditionally been thought of as ‘different’; that the rules that applied to other therapy areas were not necessarily applicable to the development of treatments for cancer patients, who until relatively recently, had exceedingly limited treatment options. Dose finding was based on the paradigm adopted for cytotoxics and was focused on identifying the maximum tolerated dose, and initial accelerated or conditional approvals were sought based on a small number of patients and surrogate endpoints often in single arm trials. However, cancer mortality rates dropped by 33% between 1991 and 2020 driven by earlier detection, reductions in smoking rates and the availability of novel therapies (American Cancer Society, 2023).

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.


Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!